Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism IL-2 inhibitors(Interleukin-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Selecxine, Inc. Co Ltd.Startup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | Selecxine, Inc. Co Ltd.Startup | 21 Dec 2022 |
Advanced Malignant Solid Neoplasm | Phase 2 | AU | Selecxine, Inc. Co Ltd.Startup | 21 Dec 2022 |
Advanced Malignant Solid Neoplasm | Phase 2 | KR | Selecxine, Inc. Co Ltd.Startup | 21 Dec 2022 |
Neoplasms | Preclinical | US | - |